Menon Biosensors, Inc. has developed a universal biomarker detection platform that provides qualitative and quantitative pathogen detection results faster and at lower cost than competing technologies. The core Molecular Mirror (M2) technology utilizes nanoparticles functionalized with biomarkers (antibodies, aptamers, nucleic acids, small molecules, etc.). Test samples (blood, sputum, stool, urine, tissue, water, powder, etc.) are mixed with reagents and gently heated to enable biomarkers to hybridize to the target, if present. The sample is then passed through a magnetic resonance system, resulting in a signal.
The Molecular Mirror technology can be implemented in various configurations depending on end user needs. For lower throughput, commercially available benchtop nuclear magnetic resonance systems (NMR) are available. On the other hand, Magnetic Resonance Imaging (MRI) systems, available at virtually every metropolitan hospital across the United States, can be configured for high-throughput screening of samples in microplates. Such a configuration could allow screening of tens of thousands of patient specimens within an hour. This would be especially helpful in pandemic situation where high-throughput testing solutions are essential for controlling the spread of disease.